Opium and its derivatives are potent analgesics that can also induce severe side effects, including respiratory depression and addiction. Opioids exert their diverse physiological effects through specific membrane-bound receptors. Three major types of opioid receptors have been described, termed 8, c, and ,t Opioids such as morphine are used clinically for the management of pain (1). However, the use of opioids has undesirable side effects-including respiratory depression, decreased gastrointestinal motility, sedation, nausea, and mood changes. Other major limitations include abuse potential, tolerance, and physical dependence. Morphine and the endogenous opioid peptides, the enkephalins, endorphins, and dynorphins, exert their physiological effects through membrane-bound receptors expressed in the central and peripheral nervous systems and in target tissues.
of seven transmembrane-spanning receptors. There is =60% amino acid identity among the sequences of the 8, K, and , opioid receptors. The sequences of the putative membranespanning segments (TM I-VII) and the three intracellular loops connecting these segments are highly conserved, whereas the sequences of the extracellular NH2-termini segments, second and third extracellular loops, and the intracellular COOH termini are divergent. It seems reasonable to assume that these divergent extracellular regions may be responsible for the distinct ligand-binding profiles ofthe 8 , K, and 1i receptors. To test this hypothesis, we have exchanged the extracellular NH2 termini of the mouse 8 and K receptors (3, 4) and examined the abilities of these chimeric receptors to bind 8-and K-selective agonists and antagonists, as well as to mediate inhibition of adenylyl cyclase activity.
METHODS
Generation of Chimeras. To exchange NH2 termini between the mouse 8 and K opioid receptors, a common restriction site, Spe I, was generated at an equivalent position in the cDNAs in the region encoding the first trainsmembrane domain without altering the amino acid sequence of either receptor. Site-directed mutagenesis was done by using the Altered Sites in vitro mutagenesis system (Promega) and 27-mer oligonucleotides containing the Spe I site (8-receptor oligonucleotide, CTGGGCAACGTACTAGTCATGTTTG-GC, and K-receptor oligonucleotide, GTGGGCAATTCAC-TAGTCATGTTTGTC). After digestion with Spe I and the appropriate 5' and/or 3' enzymes, the cDNA fragments encoding the NH2 and COOH termini of 8 and K were isolated from a 1.2% low-melting-point agarose gel. Fragments encoding the NH2 terminus of 8 receptor and the COOH terminus of K receptor and vice versa were ligated together and cloned into the mammalian expression vector pCMV-6c. Truncated 8 and K receptors were generated by ligating the fragments encoding the COOH termini directly into the expression vector. Translation of the receptor sequences in these constructs was predicted to begin at a conserved ATG just distal to the Spe I site.
Radioligand-Binding Assays. The chimeras K1 78/&70372 and 8169/K79380 (Fig. 1) were generated and transfected into COS-7 cells in parallel with either wild-type K or 8 receptor by the calcium phosphate precipitation method as described (4, 6) . For receptor-binding studies, COS-7 cells expressing the receptors were harvested 72 hr after transfection in 50 mM Tris-HCl, pH 7.8/1 mM EGTA/5 mM MgCl2/leupeptin at 10 pg/ml/pepstatin at 10 a/ml/bacitracin at 200 pg/ ml/aprotinin at 0.5 ,ug/ml (buffer 1) and centrifuged at 24,000 x g for 7 min at 4°C. The pellet was homogenized in buffer 1 using a Polytron. The homogenate was centrifuged at 48,000 x g for 20 min at 4°C, and the pellet was resuspended in buffer 1 and used in the radioligand-binding assay. Cell membranes (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) cAMP Accumulation Assays. cAMP accumulation in COS-7 cells expressing the wild-type or mutant receptors was measured as described (7) . Briefly, COS-7 cells were subcultured in 12-well culture plates. The cells were transfected 72 hr before the cAMP experiments. Culture medium was removed from the wells and replaced with 500 ul of fresh medium containing 0.5 mM isobutylmethylxanthine. Cells were incubated for 20 min at 37°C. Medium was removed and replaced with fresh medium/0.5 mM isobutylmethylxanthine with or without 10 ,uM forskolin and various opioid agonists and antagonists. The cells were incubated for 30 min at 37°C. Medium was removed, and cells were sonicated in the wells in 500 ,4 of 1 M HCL. The HCO was removed under vacuum, and the cAMP was quantified by using an RIA kit from DuPont/NEN, as described (4) . RESULTS
The Expression in COS-7 cells of the chimeric Kb-78/&70-372 conferred functional properties indistinguishable from the wild-type 8 receptor (Fig. 3 Lower). The 8-selective agonist DSLET inhibited forskolin-stimulated cAMP formation, and this effect was blocked by naltrindole (Fig. 3) Our findings suggest that antagonists interact with the NH2 terminus of the K receptor, whereas agonists bind to more distal regions, possibly the second and third extracellular loops because these are the only other extracellular domains that differ in amino acid sequence between the K and 8 receptors. Richardson et al. (8) have reported that modification of K receptors of the guinea pig cerebellum with the carbodiimide, 1-ethyl,3-(3-dimethylaminoethyl)carbodiimide (EDAC), could be prevented by selective agonists but not by antagonists. They have suggested that K-selective agonists and antagonists bind to distinct sites in the receptor because agonists, but not antagonists, were able to protect the receptor from modification by EDAC. These findings are consistent with our results, which suggest that agonists and antagonists bind to separate recognition sites in the K receptor.
Ligands have been shown to bind to the NH2 terminus of other receptors, such as the follicle-stimulating hormone and choriogonadotropin receptors (9, 10) . However, for those receptors, agonists have been shown to bind to the NH2 terminus. In contrast, antagonists selectively bind to the NH2 terminus of the K receptor, indicating a specific characteristic of this opioid receptor.
Previous studies on the ,¢adrenergic receptor and tachykinin receptor have suggested that agonists and antagonists bind to distinct domains (11) (12) (13) . However, for these receptors, the agonist-and antagonist-binding domains physically overlap. This is not the case for the K receptor, in which agonists and antagonists bind to physically separable regions. In the cases of the l3-adrenergic and tachykinin receptors, overlapping domains allow for agonists and antagonists to compete for common sites within the receptor. The unusual aspect of the K receptor is that the NH2 terminus must be able to fold upon the receptor to bring the antagonist-and agonistbinding domains in close-enough proximity to allow antagonists and agonists to compete for binding.
Whereas these chimeras distinguish the agonist-and antagonist-binding domains of the K receptor, this is not so for the 8 receptor. However, our recent mutagenesis studies (14) have shown that selective agonists and antagonists interact differently with the 8 receptor, suggesting that their binding domains may, therefore, be distinct but overlapping. Future mutagenesis studies will provide a more precise delineation of antagonist-binding domains of both the 8 and K receptors.
The results presented here indicate an unexpected difference between the K and 8 receptors with respect to the locations of agonist-and antagonist-binding domains and the important role played by the NH2-terminal 78 residues of the K receptor in antagonist binding. Furthermore, recent studies (H.K., K.R., and T.R., unpublished work) indicate that the second extracellular loop of the K receptor is a recognition site for the binding of selective agonists. The demonstration that agonists and antagonists bind to different regions of the K receptor should facilitate development of more selective K ligands. This is an area of considerable interest because K receptor-selective agents have limited abuse potential and respiratory-depressant effects (1) . The structural analysis of the ligand-binding domains of the opioid receptors will provide the basis for the rational design of another generation of therapeutically useful analgesics with limited side effects.
